Investing.com -- Dizal Jiangsu Pharmaceutical shares jumped as much as 14% on Thursday, marking the largest single-day gain since April 21, following the company’s announcement of a key regulatory approval in the United States.

The Chinese drug maker received accelerated approval from the U.S. Food and Drug Administration (FDA) for its medication Zegfrovy, also known as sunvozertinib.

The approval allows the drug to be used in adult patients with locally advanced or metastatic non-small cell lung cancer with EGRF exon 20 insertion mutations.

This regulatory milestone represents a significant development for Dizal as it expands its presence in the U.S. pharmaceutical market with a treatment targeting a rare form of lung cancer.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.